DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Comparison (standardized mortality ratio) of

• Observed incidence of deaths from start of DAA therapy in patients with hepatic decompensation (Child-Pugh B or C) in SOLAR-1 and SOLAR-2 studies
  • LDV/SOF + RBV for 12 or 24 weeks, n = 212 (123 Child B and 89 Child C)
• With mortality predicted by survival models derived from HCV patients with hepatic decompensation in the pre-DAA era

Survival model derived from liver transplant candidates with hepatic decompensation (Organ Procurement and Transplantation Network)

• Model development: HCV patients on the waiting list as of Jan 1, 2007
• Model validation: HCV patients on the waiting list as of Jan 1, 2008
• Selected patients meeting the SOLAR studies eligibility criteria

Observed versus expected mortality

• SOLAR studies: 15 deaths within 1 year of therapy
• Standardized mortality ratio: not different for the first 100 days, significantly reduced thereafter